Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Raised by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,451 shares of the medical research company's stock after purchasing an additional 10,547 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Thermo Fisher Scientific were worth $26,417,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in TMO. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 0.6% during the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company's stock valued at $16,582,503,000 after acquiring an additional 180,618 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Thermo Fisher Scientific by 6.9% during the fourth quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company's stock valued at $4,240,824,000 after acquiring an additional 517,137 shares during the last quarter. Norges Bank bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $2,909,524,000. Wellington Management Group LLP raised its stake in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company's stock valued at $1,559,351,000 after acquiring an additional 274,464 shares during the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Thermo Fisher Scientific by 16.0% during the fourth quarter. Franklin Resources Inc. now owns 2,518,760 shares of the medical research company's stock valued at $1,336,933,000 after acquiring an additional 347,560 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a research note on Thursday, April 25th. Citigroup started coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a "neutral" rating and a $620.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Finally, HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a "buy" rating in a research report on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $606.47.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company's stock, valued at $7,430,359.02. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company's stock, valued at $70,238,340.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Stock Up 1.0 %

Shares of NYSE:TMO traded up $5.40 during trading on Friday, reaching $548.09. 940,711 shares of the stock traded hands, compared to its average volume of 1,536,635. The stock has a market cap of $209.22 billion, a P/E ratio of 35.16, a price-to-earnings-growth ratio of 2.50 and a beta of 0.77. The stock has a 50-day moving average of $568.28 and a two-hundred day moving average of $563.80. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.